Long‐term outcome of patients surviving for more than ten years following treatment for acute leukaemia

Abstract

Summary. Between 1972 and 1988, 832 consecutive patients were treated for acute leukaemia at St. Bartholomew's Hospital; a retrospective analysis has been conducted to determine the clinical course and outcome for 101 who have survived $ 10 years following treatment. At a median follow-up of 16 years (range 10±28 years), 86 patients (86 out of 834 total, 11%) were still alive. Long-term follow-up of patients who have survived $ 10 years following treatment for acute leukaemia revealed that most patients were in normal health, although a significant number of complications had occurred.

Adult acute lymphoblastic leukaemia

“…Several active anti-ALL drugs including alkylators, etoposide, and radiation therapy bear the risk of second cancers [508]. The estimated incidence of secondary malignacies appear to rise over time from 0.59 and 3.63% (only secondary haematological cancers, 942/1170 patients in remission) at 5 and 10 years, respectively, as documented by a large retrospective analysis from the GIMEMA group [509], to 8 and 27% (all types of cancer) at 10 and 20 years, respectively, in a smaller series (34 patients) from Bart's Hospital [510].…”

Azelaic Acid Exerts Antileukemic Activity in Acute Myeloid Leukemia

“…Nonetheless, the overall survival of AML patients remains low due to the therapy resistance and risk of developing therapy-related malignancy. It was reported that about 13.4% of AML patients that survived for more than 10 years developed secondary tumor (Micallef et al, 2001). …”

Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr

“…Most of the QoL studies dealing with hematological malignancies focus on patients with other types of cancer such as acute lymphocytic leukemia (ALL), acute myelotic leukemia (AML) (14, 15) or mixed groups of patients with different diagnoses (16–18). Of the studies concerned with QoL in leukemia it is noted that the majority have looked at short‐ and long‐term effects in patients who have undergone bone marrow transplantation (BMT) (19–23).…”